You are here

Three-year data show early response to Saxenda® resulted in improvements in weight loss and cardiometabolic risk factors

Read the full release

Gothenburg, Sweden, 2 June 2016 - Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the first European Obesity Summit (EOS 2016). 

Further information

Katrine Sperling+45 4442
Ken Inchausti (US) +1 609 786
Peter Hugreffe Ankersen+45 3075
Melanie Raouzeos+45 3075
Kasper Veje (US)+1 609 235



Sunday, November 4, 2018 - 18:37